X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.
Lead Product(s): Stenoparib
Therapeutic Area: Oncology Product Name: 2X-121
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
The agreement provided Allarity with TKI258 (dovitinib), an oral multikinase inhibitor targeting FGF receptors, PDGF receptors and VEGF receptors, for the treatment of renal cancer.
Lead Product(s): Dovitinib
Therapeutic Area: Oncology Product Name: TKI258
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination February 02, 2024
Details:
2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.
Lead Product(s): Stenoparib
Therapeutic Area: Oncology Product Name: 2X-121
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Under the Agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol (5-fluorouracil) for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP® companion diagnostics, including its validated DRP®-5FU companion diagnostic.
Lead Product(s): Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area: Oncology Product Name: Deflexifol
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: FivepHusion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 31, 2023
Details:
2X-121 (stenoparib) is a PARP inhibitor in Phase 2 development for ovarian cancer and in Phase 1 development for advanced solid tumors in a combination treatment with dovitinib, a pan-tyrosine kinase inhibitor that has previously been developed through Phase 3 in renal cancer.
Lead Product(s): Stenoparib
Therapeutic Area: Oncology Product Name: 2X-121
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Stenoparib is a dual-targeted inhibitor of PARP 1, 2 and tankyrase 1, 2 where dovitinib is a pan-tyrosine kinase inhibitor. The combination may increase the chances of cancer apoptosis and providing synergistic, enhanced antitumor activity.
Lead Product(s): Dovitinib,Stenoparib
Therapeutic Area: Oncology Product Name: TKI258
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
The DRP® platform has proven its ability to provide a statistically significant prediction of clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®.
Lead Product(s): Dovitinib,Stenoparib
Therapeutic Area: Oncology Product Name: TKI258
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s NDA and related PMA.
Lead Product(s): Dovitinib
Therapeutic Area: Oncology Product Name: TKI258
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
NDA is supported by Allarity’s previously-filed pre-market approval submission to the FDA for the Dovitinib-DRP® companion diagnostic to select RCC patients most likely to respond to the drug.
Lead Product(s): Dovitinib
Therapeutic Area: Oncology Product Name: Dovitinib-DRP
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2021
Details:
The additional pre-clinical results show that stenoparib demonstrated antiviral activity inhibiting the delta variant in a dose-dependent manner in Vero E6 cells. The delta variant used for the experiments carries an additional deletion in ORF7a, a rapidly spreading mutation.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viroclinics Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
